Chapter 25. Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy

  1. Jack A. Roth MD, F.A.C.S.1,
  2. James D. Cox MD2 and
  3. Waun Ki Hong MD, D.M.Sc. (Hon.)3
  1. Minh Huynh and
  2. Primo N. Lara Jr

Published Online: 16 APR 2008

DOI: 10.1002/9780470696330.ch25

Lung Cancer, Third Edition

Lung Cancer, Third Edition

How to Cite

Huynh, M. and Lara, P. N. (2008) Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy, in Lung Cancer, Third Edition (eds J. A. Roth, J. D. Cox and W. K. Hong), Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470696330.ch25

Editor Information

  1. 1

    Professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic and Cardiovascular Surgery, Professor of Molecular and Cellular Oncology, Director, W.M. Keck Center for Innovative Cancer Therapies, Chief, Section of Thoracic Molecular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

  2. 2

    Professor and Head, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

  3. 3

    American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, Professor and Head, Division of Cancer Medicine Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Publication History

  1. Published Online: 16 APR 2008
  2. Published Print: 1 JAN 2008

ISBN Information

Print ISBN: 9781405151122

Online ISBN: 9780470696330

SEARCH

Keywords:

  • lung cancer;
  • cancer therapy;
  • nonsmall cell;
  • proteasome inhibition;
  • anticancer activity

Summary

This chapter contains section titled:

  • Introduction

  • Bortezomib: Potential Mechanisms of Anticancer Activity

  • Sequence Specificity of Combination Proteasome Inhibition Therapy with Chemotherapy

  • Pharmacology of Bortezomib

  • Early Phase Clinical Development

  • Single-Agent Bortezomib Studies in Advanced NSCLC

  • Proteasome Inhibition with Chemotherapy and Other Agents

  • Bortezomib in SCLC

  • Conclusion

  • References